PIN11 Assessing Lyme Disease Prevalence In The United States Medicaid Population  by Wang, L. et al.
A266  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
atric hospitalizations. Wilcoxon rank sum test was used to determine differences 
in hospital LOS. Results: Overall, these data represent over 4.6 million pediatric 
hospital discharges for SSTIs nationwide from 2001 to 2010. The rate of hospitaliza-
tion for SSTIs increased 60%, from 491/10,000 in 2001 to 784/10,000 in 2010. S. aureus 
SSTIs increased over the study period from 6/10,000 in 2001 and peaked at 37/10,000 
in 2008. This was mostly attributable to the dramatic increase in MRSA SSTIs, from 
1.3 cases per 10,000 in 2001 to 31.4 cases per 10,000 in 2010. Additionally, MSSA SSTIs 
nearly tripled throughout the study period (4 per 10,000 in 2001 to 12 per 10,000 in 
2010). The median (interquartile range) hospital LOS for S. aureus SSTIs significantly 
decreased from 3 (2-5) days in 2001 to 2 (1-3) days in 2010 (P< 0.001). ConClusions: 
The incidence of MSSA and MRSA SSTI hospitalizations among U.S. children has 
dramatically increased from 2001 to 2010.
PIN9
GRAM+ Acute BActeRIAl SkIN ANd SkIN StRuctuRe INfectIoNS (ABSSSI): 
ReceNt tReNdS IN uNIted StAteS HoSPItAl AdMISSIoNS
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objeCtives: To characterize types of hospitals and patients contributing to the 
prevalence of ABSSSI hospital admissions and describe recent admission trends in 
the US. Methods: We conducted a retrospective database analysis of adult (≥ 18 
years) hospital admissions with a principal ICD-9 diagnosis of ABSSSI: 681.XX, 682.
XX, 686.XX, 958.3, 998.5X, or 035 using the US Healthcare Cost and Utilization Project 
National Inpatient Sample (HCUP NIS), representing over 1,000 hospitals with > 8 
million hospital stays annually from 2005-2011. Descriptive and bivariate analysis 
was performed. HCUP specified weights were used for national estimates. Results: 
From 2005-2011, there were 4,891,187 adult ABSSSI hospital admissions (2% of all 
HCUP NIS admissions), with admissions increasing 17.3% across this timeframe 
(p< 0.0001). ABSSSI patients were primarily male (50.8%), white (60.3%), mean age 
55.7 years (±18.6 yrs), Medicare (40.7%), and discharged to home (53.8%). Patients 
were of moderate severity of illness (43.5% APR-DRG II) with minor risk of mortality 
(60.4% APR-DRG I). Comorbidities included diabetes without complications (25.2%), 
COPD (17.2%), and CHF (10.3%) and increased over time (p≤ 0.0001). Hospitals were 
in urban areas (85.4%), in the South (39.0%), of large bed size (> 325 beds by region, 
59.1%), private (71.0%), and with non-teaching status (55.3%). Majority of admissions 
were other cellulitis and abscess (682.XX, 73.5%) and post-operative wound infection 
(998.5X, 21.5%). Post-traumatic (958.3, n= 13,952) and post-operative wound (998.5X, 
n= 1,048,916) infection incurred the greatest mean length of stay (7.2 vs 6.7 days, 
respectively vs 4.7 days average across ABSSSI codes). Mortality was 0.5% overall and 
was highest among post-operative wound infection patients (1.1%). ConClusions: 
More ABSSSI patients enter the US hospital system each year with a greater propor-
tion having comorbidities. As the population continues to age, alternative settings 
for treating ABSSSI patients may lessen the burden on the hospital system and 
reduce potential risks associated with a hospital stay.
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ReceNt tReNdS IN INcIdeNce of INfANt PeRtuSSIS HoSPItAlIzAtIoNS IN 
tHe uNIted StAteS
Davis K.L., Kurosky S.
RTI Health Solutions, Research Triangle Park, NC, USA
objeCtives: Infants are at greatest risk for severe pertussis (~50% of infant cases 
require hospitalization). Recent surveillance indicates a resurgence of overall per-
tussis incidence in the US, but limited data exist on whether severe infantile cases 
are also resurging and the extent to which severe pertussis incidence in infants var-
ies by sex and race. We therefore assessed recent US trends in overall and sex- and 
race-stratified incidence of infant pertussis-related hospitalizations. Methods: 
Data on pertussis-related hospitalizations (ICD-9-CM discharge codes 033.0, 033.8, 
033.9, 484.3) from the 2000-2011 Nationwide Inpatient Sample (NIS) were retrospec-
tively analyzed. Annual pertussis-related hospitalizations per 10,000 infants aged 
< 12 months was estimated using NIS sampling weights and year-specific population 
denominators from US census data. Results: Incidence of pertussis-related hos-
pitalization was ~6/10,000 infants between 2000 and 2003 before increasing sharply 
in 2004 (9.0/10,000) and 2005 (13.8/10,000). Thereafter, incidence fell substantially 
(6.2, 4.1, and 4.2/10,000 in 2006, 2007, and 2008, respectively) before increasing again 
in 2009 and 2010 (5.9 and 7.8/10,000, respectively). Incidence declined again in 2011 
(3.2/10,000). Incidence was similar between males and females, but substantial dif-
ferences were observed by race. Incidence was highest in Hispanic infants, starting 
at 8.6/10,000 in 2000, peaking at 24.9/10,000 in 2005, and then falling to 4.3/10,000 
in 2008 before another sharp increase to 14.7/10,000 in 2010. Incidence was lowest 
for white and Asian infants, reaching a 2005 peak of only 5.4 and 5.3/10,000, respec-
tively. ConClusions: Infant pertussis hospitalizations peaked in 2005 before a 
sharp decline thereafter, possibly due to increased herd immunity conferred by 
the 2006 launch of universal adolescent Tdap vaccination. Incidence resurged again 
through 2010 before another decline in 2011, demonstrating for severe cases the 
documented cyclic pattern of peaks and nadirs for overall pertussis incidence. This 
analysis also highlights the need for increased focus on minorities in pertussis 
vaccination programs.
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1STATinMED Research, Dallas, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 
3STATinMED Research and The University of Michigan, Ann Arbor, MI, USA
objeCtives: To examine the geographic, age, gender and racial variations in 
the prevalent population of Lyme disease using U.S Medicaid data. Methods: 
Patients with Lyme disease were identified using International Classification of 
and deaths, respectively, may have been QIV-preventable. ConClusions: The 
seasonal variability of influenza B lineage circulation and the level of vaccine 
match determine the extent of the benefit of QIV use. However, on average, under 
reasonable assumptions of vaccine effectiveness, a substantial number of hospi-
talizations and deaths could have been prevented by using QIV during the study 
period in the United States. Funding: GlaxoSmithKline Biologicals SA
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ASSocIAtIoN BetweeN INteRfeRoN uSe ANd Reduced MetABolIc ANd 
vASculAR coMPlIcAtIoNS AMoNG PAtIeNtS wItH HePAtItIS c
Chirikov V.V.1, Shaya F.T.1, Howell C.D.2
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objeCtives: We determined the association between interferon treatment for 
chronic hepatitis C (HCV) and the presence and severity of metabolic and vas-
cular complications over time in a high-risk Medicaid population. Methods: 
This was a historical prospective cohort study using administrative claims data 
of Maryland Medicaid recipients (2006-2009) infected with hepatitis C. We used 
the validated Diabetes Complications Severity Index (DCSI) as proxy for the pres-
ence and severity of metabolic and vascular complications. The endpoint of the 
study was the change in DCSI score during three years of follow-up. At baseline, 
interferon-treated patients were matched 1:10 to non-treated patients for DCSI 
count, cirrhosis, end stage liver disease, race, and anti-diabetic therapy. We modelled 
the association between interferon use and the risk of the presence and increased 
severity of vascular and metabolic complications using a zero-inflated Poisson mul-
tivariate regression, stratified by White and Black race and adjusted for baseline 
covariates. Results: White persons treated with interferon for 24-48 weeks and 
longer than 48 weeks had a significantly smaller increase in DCSI score ranging 
from 53%-75% and 54%-69% over the study follow-up, respectively, compared to 
untreated persons. There was no significant difference in the change in DSCI scores 
in Blacks treated for either 24-48 weeks or longer than 48 weeks, though paradoxi-
cally Blacks treated for > 48 weeks had a borderline significant 45% higher DSCI 
score at 30 months of follow-up. In patients with a DSCI count of zero at baseline, 
both White (OR= 0.22, P= 0.01) and Black (OR= 0.38, P= 0.09) patients treated with 
interferon exhibited a lower risk of developing vascular/metabolic disease at 30 
and 36 months of follow-up, respectively. ConClusions: The results suggest that 
interferon treatment for chronic HCV might decrease metabolic and vascular com-
plications related to diabetes.
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evAluAtIoN loNG-teRM effectS of tReAtMeNt ANd ReSPoNSe oN 
HeAltH RelAted QuAlIty of lIfe AMoNG PAtIeNtS wItH cHRoNIc 
HePAtItIS c
Almadiyeva A., Kostyuk A., Ibrayev S., Salpynov Z.
Astana Medical University, Astana, Kazakhstan
objeCtives: Hepatitis C decreases health related quality of life (HRQL) which 
is further diminished by dual antiviral therapy. HRQL improves after successful 
treatment. This trial explores the course of and factors associated with HRQL in 
patients given individualized or standard treatment based on early treatment 
response. To study the relationship betweenv HRQL and mode of acquisition, treat-
ment discontinuations and treatment outcome in patients with chronic hepatitis 
C. Methods: The Short Form SF-36 Health Survey was administered for evaluation 
health-related quality of life. Consecutive unselected Kazakh patients with chronic 
hepatitis C completed the SF-36 questionnaire before, during and after treatment 
with pegylated interferon and ribavirin before, during and after combination ther-
apy. Results: At baseline, HRQL was reduced in all SF-36 subscales in our patients 
as compared with the general Kazakh population by age, participating center, sever-
ity of liver disease and income. Exploring the course of HRQL (scores at follow up 
minus baseline), only the dimension general health increased. In this dimension 
patients with a relapse or sustained response differed from non-responders. Men 
and women differed in the dimension bodily pain. Treatment schedule did not influ-
ence the course of HRQL. ConClusions: Kazakh patients with chronic hepatitis 
C have a marked reduction in their HRQL as compared to the general population. 
Main determinants of HRQL were severity of liver disease, age, gender, participating 
center and response to treatment. Our results do not exclude a more profound nega-
tive impact of individualized treatment compared to standard, possibly caused by 
higher doses and extended treatment duration in the individualized group. Antiviral 
therapy might have a more intense and more prolonged negative impact on females. 
Early dropouts from therapy have significantly lower HRQL scores at baseline than 
adherent patients, and sustained viral responders improve their HRQL significantly 
more than non-responders.
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tHe RISe of HoSPItAlIzAtIoNS due to StAPHylococcuS AuReuS SkIN ANd 
Soft tISSue INfectIoNS (SStIS) AMoNG uNIted StAteS cHIldReN fRoM 
2001 to 2010
Lee G.C., Reveles K.R., Boyd N.K., Frei C.R.
The University of Texas at Austin and The University of Texas Health Science Center at San 
Antonio, San Antonio, TX, USA
objeCtives: Estimating the burden of Staphylococcus aureus infections among U.S. 
children is important for planning appropriate prevention and treatment strategies. 
The objectives of this study were to characterize national estimates of S. aureus 
SSTIs in pediatric patients from 2001 to 2010 and assess trends in hospital length 
of stay (LOS). Methods: This was a retrospective analysis of the U.S. National 
Hospital Discharge Surveys from 2001 to 2010. Eligible cases included children < 
18 years of age hospitalized with a principle ICD-9-CM diagnosis code for SSTI. 
S. aureus, methicillin-susceptible S. aureus (MSSA), and methicillin-resistant S. 
aureus(MRSA) were defined by ICD-9 CM diagnosis codes. Data weights were used 
to derive national estimates. Annual incidence rates were reported per 10,000 pedi-
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PRevAleNce of HIv ANd coMoRBId BuRdeN AMoNG PeoPle 65 ANd oldeR 
IN tHe uNIted StAteS
Farr A.M.
Truven Health Analytics Inc, Cambridge, MA, USA
objeCtives: Antiretroviral medications have extended the lives of persons living 
with HIV. As a result, the United States health care system will face challenges posed 
by an aging HIV+ population. This analysis describes the incidence and prevalence 
of HIV among individuals 65 years and older and characterizes the comorbid disease 
burden of these patients. Methods: This retrospective analysis utilized Truven 
Health MarketScan® Commercial and Medicare Supplemental administrative health 
care claims. Prevalence and incidence were calculated for patients aged ≥ 65 for 
2005-2012. Patients with ≥ 1 non-diagnostic medical claim with an ICD-9-CM code 
for HIV (V08, 042) were considered to be HIV+. The first claim with an HIV diagnosis 
was referred to as the index date. Incident patients must have been enrolled for ≥ 6 
months prior to index date with no evidence of HIV diagnosis. Prevalent patients 
must have been enrolled for ≥ 3 months before and after a claim with HIV diagno-
sis within a given year to evaluate comorbid conditions. The earliest claim within 
the year meeting enrollment criteria was used. Denominators for prevalence and 
incidence were the number of individuals with ≥ 6 months of continuous enroll-
ment. Comorbidities were defined as ≥ 1 non-diagnostic claim with ICD-9-CM code 
for individual components of the Deyo Charlson Comorbidity Index. Results: 
The prevalence of HIV doubled from 2005 (22.5 cases per 100,000) to 2012 (46.9 
cases), while incidence decreased (2005= 11.2 per 100,000; 2012= 6.7). The mean age 
of prevalent cases decreased slightly from 71.8 years (SD 6.1) in 2005 to 69.9 (SD 
5.2) in 2012. The mean age of incident cases was 73.3 (SD 7.2). The most common 
comorbid conditions were chronic pulmonary disease (average proportion across 
years= 15.1%), diabetes (19.0%), and malignancy (14.7%). ConClusions: Prevalence 
of HIV is increasing among those 65 and older and health systems must prepare to 
deliver care to older HIV+ patients with comorbid conditions.
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exAMINING HePAtItIS c vIRuS PRevAleNce IN tHe uNIted StAteS 
MedIcAId PoPulAtIoN fRoM 2008 to 2009
Xie L.1, Wang L.2, Zhang J.2, Shrestha S.2, Wang Y.1, Baser O.3
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objeCtives: The study purpose was to examine hepatitis C virus (HCV) prevalence, 
and geographic, age, gender and racial variations within the U.S. Medicaid popula-
tion. Methods: HCV patients were identified from the Medicaid fee-for-service 
(FFS) population using International Classification of Disease, 9th Revision, Clinical 
Modification (ICD-9-CM) diagnosis codes 070.41, 070.44, 070.51, 070.54 and V02.62 for 
this retrospective study (01JAN2008-31DEC2009). All patients were required to have 
2 years of continuous Medicaid FFS enrollment and no managed care enrollment 
in any month during the study period. HCV prevalence was analyzed by region, 
state, age, gender and race. Numbers and percentages were calculated to measure 
prevalence within the sample. Results: A total of 42,183 HCV patients (0.86%) 
were identified from the Medicaid FFS population in 2008 and 2009. Patients who 
were age 40-59 years were found to have the highest prevalence (2.61%), compared 
to those age 60+ (0.38%) and 0-39 years (0.27%). Prevalence analysis by race showed 
the following results: Black (1.28%), Hispanic (1.06%), White (0.74%), Asian (0.53%) 
and Native American (0.39%). In the study sample, male patients had a relatively 
higher prevalence (1.23%) than female patients (0.63%). HCV prevalence was also 
examined by U.S. state, with the highest HCV prevalence observed in Connecticut 
(2.59%), followed by Rhode Island (2.19%), New York (1.82%), Maryland (1.79%) and 
Missouri (1.71%). The highest prevalence rates were found in the Northeast (1.44%) 
compared to the Midwest (0.87%), South (0.52%) and West (0.49%). ConClusions: 
Middle-aged patients have a higher probability of being diagnosed with HCV infec-
tion. Analysis by patient gender and race revealed that male and Black patients were 
at a higher risk for an HCV diagnosis. Additionally, patients residing in the Northeast 
were more likely to be diagnosed with an HCV infection.
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objeCtives: To examine the geographic, age, gender and racial variations of hepa-
titis B virus (HBV) infection prevalence in the U.S. Medicaid population. Methods: 
A retrospective study was conducted among the Medicaid fee-for-service (FFS) 
population in 2008 and 2009. Patients with an HBV diagnosis were identified using 
International Classification of Disease, Clinical Modification (ICD-9-CM) diagnosis 
codes 070.22, 070.23, 070.32, 070.33 and V02.61. Two years of continuous Medicaid 
FFS enrollment were required, and patients with managed care enrollment during 
the study period were excluded. HBV prevalence was stratified by region, state, age, 
gender and race. Descriptive statistics were calculated as number and percentage 
of patients in each category. Results: A total of 5,944 patients (0.12%) were diag-
nosed with HBV in 2008 and 2009. For HBV patients age 40-59 years, prevalence 
was the highest at 0.30%, followed by age group 60+ at 0.08%, and 0-39 at 0.05%. 
Prevalence stratified by race was examined, and Asian patients had the highest rate 
at 0.95%, compared to Black (0.17%), Hispanic (0.11%), Native American (0.09%) and 
White (0.08%) patients. Male patients were found to have a relative higher preva-
lence of HBV than female patients in the Medicaid population (0.19% vs. 0.08%). 
Geographic variation was analyzed, and the highest HBV prevalence was observed 
in Washington, DC (1.30%), followed by New York (0.35%), Minnesota (0.32%), Alaska 
(0.25%) and Connecticut (0.24%). The Northeastern U.S. region was found to have 
the highest prevalence (0.24%), compared to the Midwest (0.10%), South (0.06%) 
and West (0.06%). ConClusions: Middle-aged patients had a higher probability 
Disease, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code 088.81 from 
the Medicaid fee-for-service (FFS) population in 2008 and 2009. All patients were 
required to have 2 years of continuous Medicaid FFS enrollment and no man-
aged care enrollment for any month during the study period. Disease prevalence 
was stratified by region, state, age, gender and race for all patients. Numbers 
and percentages of patients in each category were calculated in the descriptive 
analysis to measure prevalence. Results: A total of 2,110 patients (0.04%) were 
diagnosed with Lyme disease in 2008 and 2009. Prevalence was the highest at 
0.08% for patients age 40-59 years, compared to those under age 40 (0.05%) and 
over age 60 (0.02%). Race variation analysis showed the highest Lyme disease 
prevalence in White patients (0.06%), followed by Asian (0.05%), Native American 
(0.03%), Hispanic (0.02%) and Black (0.01%). There was no gender variation in Lyme 
disease prevalence (0.04%) in the Medicaid FFS population. Prevalence, stratified 
by U.S. state, was also examined. The highest prevalence rates were found in 
Connecticut (0.28%), New Hampshire (0.27%), Rhode Island (0.21%), Maryland 
(0.18%) and Minnesota (0.12%). According to U.S. region, the Northeast (0.10%) 
had the highest prevalence rate, followed by the Midwest (0.03%), South (0.02%) 
and West (0.00%). ConClusions: Middle-aged patients were shown to have a 
higher probability for a Lyme disease diagnosis. Stratified by race, White patients 
were more likely to be diagnosed with Lyme disease compared to all other races. 
There is also statistical evidence that patients located in the Northeastern U.S. 
region have a higher risk for a Lyme disease diagnosis.
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ReGIoNAl ANd SeASoNAl vARIAtIoNS IN CLoSTRIDIUM DIffICILE INfectIoNS 
IN uNIted StAteS HoSPItAlS, 2001 to 2010
Reveles K.R., Lee G.C., Boyd N.K., Frei C.R.
The University of Texas at Austin and The University of Texas Health Science Center at San 
Antonio, San Antonio, TX, USA
objeCtives: Prior studies have demonstrated increasing Clostridium difficile infec-
tions (CDI) in United States (U.S.) hospitals; however, it is unknown if regional 
or seasonal differences exist. This study identifies regional and seasonal varia-
tions in CDI incidence and mortality among hospitalized adults over a ten-year 
period. Methods: This was a retrospective analysis of the U.S. National Hospital 
Discharge Surveys from 2001 to 2010. Eligible cases included adults ≥ 18 years of 
age with an ICD-9-CM diagnosis code for CDI (008.45). Data weights were used to 
derive national estimates. Mortality and CDI incidence were presented descrip-
tively. CDI incidence rates were calculated as CDI discharges per 1,000 total adult 
discharges. Regions included the Northeast, Midwest, South, and West as defined 
by the U.S. Census Bureau. Seasons included: Winter (December-February), Spring 
(March-May), Summer (June-August), and Fall (September-November). Results: 
These data represent 2.2 million adult CDI discharges. CDI incidence was highest in 
the Northeast (9.2 CDI discharges/1,000 total discharges), followed by the Midwest 
(7.4 CDI discharges/1,000 total discharges), South (5.9 CDI discharges/1,000 total 
discharges), and West (5.7 CDI discharges/1,000 total discharges). Rates increased 
in all regions through 2008. Although, rates declined in the Northeast, Midwest, 
and West since 2008, rates in the South continued to increase until study end. CDI 
incidence was highest in the Spring (7.2 CDI discharges/1,000 total discharges), 
followed by the Summer (6.9 CDI discharges/1,000 total discharges), Winter (6.8 
CDI discharges/1,000 total discharges), and Fall (6.6 CDI discharges/1,000 total dis-
charges). Rates increased in all seasons over the study period, but have declined in 
the Fall since 2008. Mortality among CDI patients was highest in the Midwest (7.5%) 
and during the Winter (8.5%). ConClusions: CDI increased for all regions over the 
study period, and was highest in the Northeast. Peak CDI incidence occurred in the 
Spring, but mortality was highest in the Winter.
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ASSeSSING tHe INcIdeNce ANd tReAtMeNt of PoSt-tReAtMeNt lyMe 
dISeASe SyNdRoMe IN AN AdMINIStRAtIve clAIMS dAtABASe
Montejano L.B.
Truven Health Analytics, Cambridge, MA, USA
objeCtives: Post-Treatment Lyme Disease Syndrome (PTLDS) refers to persistent 
musculoskeletal and neurological symptoms after antibiotic treatment for Lyme 
disease (LD). This study’s objectives were to examine real-world PTLDS incidence 
and treatment patterns, and assess the utility of administrative claims data to 
measure PTLDS outcomes. Methods: Patients with an LD diagnosis (ICD-9 088.81) 
between 2010-2012 and ≥ 14 days supply of first-line oral antibiotics (amoxicillin, 
doxycycline, cefuroxime axetil) were identified using Truven Health MarketScan® 
Treatment Pathways. PTLDS was measured from inpatient/outpatient claims 6-12 
months after LD diagnosis (index), using relevant symptoms, signs and ill-defined 
condition codes (ICD-9 780-799) and other related codes because PTLDS does not 
have a specific code. Treatments were measured from outpatient pharmacy claims 
and procedure codes. Results: Patients (N= 13,436) were 53% male, with a mean age 
of 41. Most (73%) resided in New England and the Mid Atlantic. PTLDS symptoms of 
headache, stiff neck, sleep disturbance and memory/cognitive problems were coded 
on claims 6-12 months post-index for 8% of patients. A broader constellation of 
PTLDS symptoms including paresthesias, visual/hearing disturbances, lightheaded-
ness and depression was coded for 14%. Seventeen percent had claims indicative of 
musculoskeletal symptoms. Median first-line antibiotic days supply over 12 months 
was 24 days. Five percent of patients had > 90 days supply over 12 months. Three 
percent received parenteral antibiotics. Patients with PTLDS-related claims had 
longer antibiotic days supply than patients without PTLDS-related claims (p< 0.001). 
Trends were similar for adults and children, but PTLDS incidence and average anti-
biotic days supply were higher among adults. ConClusions: PTLDS rates in this 
study correspond with previous research, suggesting PTLDS case identification in 
claims data may be feasible. Experts disagree about long-term antibiotic treatment 
for PTLDS; only a small proportion of patients in this study received this treatment. 
Future research is needed to help resolve controversies surrounding appropriate 
PTLDS treatment.
